Lupin has launched sugammadex injection, available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials, in the United States following approval of its Abbreviated New Drug Application by the United States Food and Drug Administration (US FDA).
Bioequivalent to Merck’s Bridion injection, Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery.
Headquartered in Mumbai, Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women’s health.
Lupin has 15 state-of-the-art manufacturing sites and seven research centers globally. Its subsidiaries include Lupin Diagnostics, Lupin Digital Health and Lupin Manufacturing Solutions.
